6Lun·

Novo Nordisk is sold off.

The reason? An experimental therapy for the treatment of obesity has failed to meet expectations.

The drug CagriSema achieved a weight loss of 22.7% in a phase 3 trial with obesity patients. Novo Nordisk had originally expected a reduction of up to 25%.

I seized the opportunity and finally bought in. I will now continue to buy more. 📈

20.12

Novo Nordisk

Compró 7 a 79,98 €

559,86 €

6 Comentarios

Kill_Baulitz@Johann_van_der_Smut

6Lun

It's totally silly and exaggerated to penalize the title like that. The efficiency of Wegovy is already above what is healthy for the body in terms of weight loss in relation to time.
What do people think? Eating roast meat and booze every day and getting slim in no time thanks to medication?
The market participants are getting more and more stupid...

•

Pope Donkey XXI@DonkeyInvestor

6Lun

22.7% is still fully within the range of "up to 25%" 🤷

•

Patrick Schäfer@Hotte1909

6Lun

@DonkeyInvestor I have rarely seen such an exaggerated market situation.

•

Andre@DivGrowth1989

6Lun

I agree...just keep your head down. The obesity patient will probably not care whether he has lost 25% or only 22.765368% in 68 weeks, the main thing is that it helps in the long term...

••

Maximilian@Max095

6Lun

Snapper price long-term 🚀🤑

••

Patrick Schäfer@Hotte1909

6Lun

@Max095 is just the medical sector. It's really difficult to analyze, but I also think it's a buying opportunity that comes along every few years. Corona peak phase of the drug manufacturers aside. That was a one-off that will hopefully never be repeated

•